Physician profile
Patrick C Nef
NPI 1194901330
$1,929.61
in general payments reported to CMS, 2019-2025
18 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $208 · 2021: $153 · 2022: $233 · 2023: $103 · 2024: $247 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $412.45 | 2024-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $278.17 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $244.50 | 2019 | |
| Glaxosmithkline, LLC. | $242.05 | 2020-2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $223.90 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $111.62 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $89.30 | 2019-2022 | |
| Novo Nordisk INC | $58.55 | 2025 | Ozempic |
| Aurinia Pharma U.S., INC. | $54.37 | 2021-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $52.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.48 | 2024 | Jardiance |
| Shire North American Group INC | $25.24 | 2019 | |
| Boston Scientific Corporation | $22.80 | 2022 | |
| Merck Sharp & Dohme LLC | $20.35 | 2025 | Prevymis |
| Novartis Pharmaceuticals Corporation | $20.25 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $15.91 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.39 | 2019 | |
| Cook Medical LLC | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Nef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.